Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 15,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Product Clear all

Conditions: NASH
Interventions: Midazolam, Caffeine, Rosuvastatin, EDP-305; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Ovarian Cancer
Interventions: AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD), Placebo; Drug · Other
Lead sponsor: Aravive, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Tucson, Arizona • Oakland, California + 12 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: San Diego, California • San Marcos, California • Aurora, Colorado + 20 more

Conditions: Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Interventions: XOPH5 Ointment, Placebo; Drug
Lead sponsor: Topokine Therapeutics, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Barrett's Esophagus, High Grade Dysplasia, Low Grade Dysplasia
Interventions: CryoSpray Ablation System (510(k) NO: K070893); Device
Lead sponsor: CSA Medical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 16
States / cities: Orange, California • Norwalk, Connecticut • Tampa, Florida + 12 more

Conditions: Lewy Body Dementia, Parkinson Disease
Interventions: Sitagliptin, Dapagliflozin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: pump, insulin aspart; Device · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: Chula Vista, California • Miami, Florida • Witchita, Kansas + 3 more

Conditions: Healthy Participants
Interventions: Povorcitinib, Levonorgestrel/Ethinyl estradiol; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
Interventions: PF-07062119, Anti-PD1, Anti-VEGF; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 6 more

Conditions: Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases, Mitochondrial Diseases, Mitochondrial Dysfunction, Genetic Disease
Interventions: ATI-105, Placebo; Drug
Lead sponsor: Adjuvia Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions: IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more

Conditions: Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
Interventions: CTM, Placebo; Device · Other
Lead sponsor: Indiana Hand to Shoulder Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions: Radiation Therapy, Pertuzumab, Trastuzumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Evanston, Illinois

Conditions: Multiple Sclerosis
Interventions: Tolebrutinib, gemfibrozil, rifampicin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Atrial Fibrillation
Interventions: Medtronic PulseSelect Pulsed Field Ablation (PFA) System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Loveland, Colorado • Washington D.C., District of Columbia + 24 more

Conditions: Xerostomia
Interventions: Biotene mouthwash, Mineral Water; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions: antitumor drug screening assay, chemotherapy, biological therapy; Other · Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: casopitant, dolasetron, granisetron, rosiglitazone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
Interventions: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker; Drug · Other
Lead sponsor: Lifespan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cranston, Rhode Island

Conditions: Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions: Discontinuation and Reinitiation of Tirzepatide; Other
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: F-Var3 PET/CT, Blood draw; Diagnostic Test · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcoholic Intoxication, Alcoholism, Healthy
Interventions: Not listed
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 2,220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Portal Hypertension
Interventions: Placebo, Cobiprostone; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diarrhea
Interventions: ACE527, dmLT, CeraVacx placebo, H10407 challenge strain; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 50 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus

Anti-Diabetic Medications to Fight PD and LBD

A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults

Prevention of Serious Adverse Events Following Angiography

Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF

Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Implementing Low-Barrier HCV Treatment in a Jail Setting

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults